MedPath

HEALIOS K.K.

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:0
Completed:6

Trial Phases

3 Phases

Phase 1:3
Phase 2:7
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 2
7 (63.6%)
Phase 1
3 (27.3%)
Phase 3
1 (9.1%)

MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Phase 2
Recruiting
Conditions
Trauma
Adult Stem Cells
First Posted Date
2020-08-31
Last Posted Date
2024-05-24
Lead Sponsor
Healios K.K.
Target Recruit Count
156
Registration Number
NCT04533464
Locations
🇺🇸

Healios Investigational Site, Houston, Texas, United States

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

Phase 2
Conditions
ARDS
First Posted Date
2020-04-29
Last Posted Date
2021-09-09
Lead Sponsor
Healios K.K.
Target Recruit Count
400
Registration Number
NCT04367077
Locations
🇺🇸

Athersys Investigational Site 107, Chicago, Illinois, United States

🇺🇸

Athersys Investigational Site 103, Akron, Ohio, United States

🇺🇸

Athersys Investigational Site 101, Cleveland, Ohio, United States

and more 1 locations

Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome

Phase 2
Completed
Conditions
Respiratory Distress Syndrome, Adult
First Posted Date
2019-01-17
Last Posted Date
2024-01-17
Lead Sponsor
Healios K.K.
Target Recruit Count
35
Registration Number
NCT03807804
Locations
🇯🇵

Investigational Site Number 027, Nagoya, Aichi, Japan

🇯🇵

Investigational Site Number 028, Nagoya, Aichi, Japan

🇯🇵

Investigational Site Number 005, Seto, Aichi, Japan

and more 26 locations

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study

Phase 3
Conditions
Ischemic Stroke
First Posted Date
2018-06-04
Last Posted Date
2022-02-09
Lead Sponsor
Healios K.K.
Target Recruit Count
300
Registration Number
NCT03545607
Locations
🇺🇸

Athersys Investigational Site 128, Phoenix, Arizona, United States

🇺🇸

Athersys Investigational Site 122, Palo Alto, California, United States

🇺🇸

Athersys Investigational Site 127, Sacramento, California, United States

and more 23 locations

Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements

Phase 2
Completed
Conditions
Stroke, Acute
First Posted Date
2016-11-11
Last Posted Date
2024-01-17
Lead Sponsor
Healios K.K.
Target Recruit Count
206
Registration Number
NCT02961504
Locations
🇯🇵

Hokkaido University Hospital, Sapporo, Japan

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.